Description de l'entreprise
Heidelberg Pharma AG based in Ladenburg, Germany, is a biopharmaceutical company listed on the Frankfurt Stock Exchange in the Regulated Market / Prime Standard. Heidelberg Pharma is focused on oncology and is the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary platform is being applied to develop the Company’s own therapeutic ATACs and third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA-ATAC for multiple myeloma. Furthermore, Heidelberg Pharma offers preclinical contract research services.
Conseil d'administration & Conseil de surveillance
| PDG |
| - |
| Conseil d'administration |
| Dr. Jan Schmidt-Brand, Prof. Dr. Andreas Pahl |
| Conseil de surveillance |
| Prof. Dr. Christof Hettich, Dr. Georg F. Baur, Dr. Birgit Kudlek, Dr. Friedrich von Bohlen und Halbach, Dr. Mathias Hothum |
Données de l'entreprise
| Nom: |
Heidelberg Pharma AG |
| Adresse: |
Gregor-Mendel-Straße 22,D-68526 Ladenburg |
| Téléphone: |
+49-6203-1009-0 |
| Fax: |
+49-6203-1009-19 |
| Courriel: |
info@hdpharma.com
|
| Internet: |
heidelberg-pharma.com/ |
| Industrie: |
Biotechnology |
| Secteur: |
Biotechnology |
| Sous-secteur: |
Biotechnology |
| Fin de l'exercice financier: |
30/11 |
| Flotte libre: |
15.33% |
| IPO date: |
13/11/2006 |
Relations avec les investisseurs
| Nom: |
Sylvia Wimmer |
| Téléphone IR: |
+49-89-413138-29 |
| IR-Fax: |
- |
| E-mail IR: |
investors@hdpharma.com
|
